Latest Lawrence Corey Stories
Herpes is an infectious disease that affects more than 24 million people in the United States alone. Now, researchers have identified a class of immune cells that exist in genital skin and mucosa that may play a role in developing a vaccine to prevent one of the most common sexually transmitted infections (STIs) in America.
SEATTLE, July 30 /PRNewswire/ -- The Fred Hutchinson Cancer Research Center board of trustees today announced the selection of Lawrence Corey, M.D., an internationally renowned expert in virology, immunology and vaccine development, as its new president and director.
Research from a five-year international clinical study shows that acyclovir, a commonly prescribed drug used to suppress symptoms of the herpes virus, does not affect HIV transmission by people with both viruses.
New research helps explain why infection with herpes simplex virus-2 (HSV-2), which causes genital herpes, increases the risk for HIV infection even after successful treatment heals the genital skin sores and breaks that often result from HSV-2.
Acyclovir, a drug that suppresses herpes simplex virus-2, does not reduce HIV risk when taken by people infected by HIV and herpes, U.S. researchers said. The majority of people with HIV infection also have herpes simplex virus-2 infection.
SEATTLE, Dec. 16 /PRNewswire/ -- The Washington Life Sciences Discovery Fund (LSDF) has awarded nearly $4.7 million to launch the start-up phase of the Washington Vaccine Alliance (WAVA) and to support initial research into three new vaccines for E. coli, herpes and syphilis.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.